Post-licensure surveillance of 13-valent pneumococcal conjugate vaccine (PCV13) in adults aged ⩾19years old in the United States, Vaccine Adverse Event Reporting System (VAERS), June 1, 2012-December 31, 2015.

There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

Abstract

The 13-valent pneumococcal conjugate vaccine (PCV13) was first recommended for use in adults aged ⩾19years with immunocompromising conditions in June 2012. On August 2014, the Advisory Committee on Immunization Practices (ACIP) recommended routine use of PCV13 among adults aged ⩾65years.

Related collections

Author and article information

Journal

Journal ID (iso-abbrev): Vaccine

Title: Vaccine

Publisher: Elsevier BV

ISSN (Electronic): 1873-2518

ISSN (Print): 0264-410X

Publication date (Electronic): December 07 2016

Volume: 34

Issue: 50

Affiliations

[1 ] Immunization Safety Office, Division of Healthcare Quality Promotion, National Center for Emerging and Zoonotic Infectious Diseases (NCEZID), Centers for Disease Control and Prevention (CDC), 1600 Clifton Rd NE, Atlanta, GA 30329, United States. Electronic address: PHaber@cdc.gov.

[2 ] Immunization Safety Office, Division of Healthcare Quality Promotion, National Center for Emerging and Zoonotic Infectious Diseases (NCEZID), Centers for Disease Control and Prevention (CDC), 1600 Clifton Rd NE, Atlanta, GA 30329, United States.

[3 ] National Center for Immunization and Respiratory Diseases (NCIRD), Centers for Disease Control and Prevention (CDC), 1600 Clifton Rd NE, Atlanta, GA 30329, United States.

Article

Publisher Item ID: S0264-410X(16)30987-2

DOI: 10.1016/j.vaccine.2016.10.052

PubMed ID: 27836437

SO-VID: 19567084-5f9b-4934-9fc3-d22375490d29

History

Keywords: Post-licensure surveillance,Vaccine safety,13-Valent pneumococcal conjugate vaccine (PCV13)

Data availability:

Keywords: Post-licensure surveillance, Vaccine safety, 13-Valent pneumococcal conjugate vaccine (PCV13)

Post-licensure surveillance of 13-valent pneumococcal conjugate vaccine (PCV13) in adults aged ⩾19years old in the United States, Vaccine Adverse Event Reporting System (VAERS), June 1, 2012-December 31, 2015.

Read this article at

Abstract

Related collections

Malaria vaccine development

Author and article information

Journal

Affiliations

Article

History

Comments

Comment on this article

Similar content 200

Cited by 6